RNA-based therapeutic strategies for cancer

Bibliography

• READ ML, BREMNER KH: Antisense strategies and non-viral gene therapy for cancer. Expert Opin Ther: Patents (2002) 12:379–391.
   Web of Science ®Google Scholar
• BETTINGER T, READ ML: Recent developments in RNA-based strategies for cancer gene therapy. Curr. Opin. Mol. Ther. (2001) 3:116–124.
   PubMedGoogle Scholar
• AOKI Y, CIOCA D, OIDAIRA H et at.: RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. Phannacol Physiol (2003) 30:96–102.
   Google Scholar
• CIOCA DP, AOKI Y, KIYOSAWA K: RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. (2003) 10:125–133.
   PubMed Web of Science ®Google Scholar
• WILDA M, FUCHS U, WOSSMANN W et al.: Killing of leukemic cells with a BCR/ ABL fusion gene by RNA interference (RNAi). Oncogene (2002) 21:5716–5724.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494–498.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of siRNA-mediatedgene silencing in mammalian cells.
   Google Scholar
• ELBASHIR SM, MARTINEZ J, PATKANIOWSKA A et al: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO (2001) 20:6877–6888.
   PubMed Web of Science ®Google Scholar
• WENG DE, USMAN N: Angiozyme: a novel angiogenesis inhibitor. Curt: Oncol Rep. (2001) 3:141–146.
   PubMedGoogle Scholar
• HALE SJ, GREEN NK: Viral approaches to cancer gene therapy. Expert Opin. Ther. Patents (2002) 12:369–378.
   Web of Science ®Google Scholar
• BUCKLEY RH: Gene therapy for SCID-a complication after remarkable progress. Lancet (2002) 360:1185–1186.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.' Gene Med. (2003) 5:82–84.
   Google Scholar
• KHROMYKH AA: Replicon-based vectors of positive strand RNA viruses. Curt: Opin. Ther. (2000) 2:555–569.
   PubMed Web of Science ®Google Scholar
• •An excellent review describing the development of novel antiviral and anticancer vaccines based on self-replicating RNAs.
   Google Scholar
• FIRE A, XU S, MONTGOMERY MK et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806–811.
   PubMed Web of Science ®Google Scholar
• ••This report describes the discovery of theRNAi phenomenon in the nematode worm Caenorhabditis elegansas a response to dsRNA.
   Google Scholar
• HANNON GJ: RNA interference. Nature (2002) 418:244–251.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the currentmechanistic model of RNAi in various organisms.
   Google Scholar
• TUSCHL T, ZAMORE PD, LEHMANN R et al.: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. (1999) 13:3191–3197.
   PubMed Web of Science ®Google Scholar
• ZAMORE PD, TUSCHL T, SHARP PA et al.: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Ce//(2000) 101:25–33.
   Google Scholar
• GIL J, ESTEBAN M: Induction of apoptosisby the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis (2000) 5:107–114.
   PubMed Web of Science ®Google Scholar
• READ ML, FARROW PJ, SEYMOUR LW: Emerging developments in RNA therapeutics. Expert Opin. Ther. Targets (2003) 7:299–303.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M: Ribozyme therapeutics.' Investig. Dermatol Symp. Proc. (2002) 7:76–78.
   PubMed Web of Science ®Google Scholar
• USMAN N, BLATT LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. Clin. Invest. (2000) 106:1197–1202.
   Google Scholar
• KHAZAIE K, SCHIRRMACHER V, LICHTNER RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev (1993) 12:255–274.
   PubMed Web of Science ®Google Scholar
• JARDINES L, WEISS M, FOWBLE B et A: Neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGER) in breast cancer. Pathobiology (1993) 61:268–282.
   PubMed Web of Science ®Google Scholar
• SCHECHTER AL, STERN DF, VAIDYANATHAN L et al: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature (1984) 312:513–516.
   PubMed Web of Science ®Google Scholar
• KRAUS MH, ISSING W, MIKI T et al.: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA (1989) 86:9193–9197.
   PubMed Web of Science ®Google Scholar
• PLOWMAN GD, CULOUSCOU JM, WHITNEY GS et al.: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Nati Acad. Sci. USA (1993) 90:1746–1750.
   PubMed Web of Science ®Google Scholar
• HYNES NE, STERN DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta (1994) 1198:165–184.
   PubMed Web of Science ®Google Scholar
• TANG CK, CONCEPCION XZ, MILAN M et al.: Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. (1999) 59:5315–5322.
   PubMed Web of Science ®Google Scholar
• LAVROVSKY Y, TYAGI RK, CHEN S et al.: Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells. Endocrinol. (1999) 13:925–934.
   Web of Science ®Google Scholar
• PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Gin. Cancer Res. (2000) 6:2094–2103.
   Web of Science ®Google Scholar
• ••The first demonstration that syntheticribozymes targeting vascular endothelial growth factor receptor mRNA can reduce the growth and metastasis of solid tumours in vivo.
   Google Scholar
• SANDBERG JA, BOUHANA KS, GALLEGOS AM et al.: Pharmacokinetics of an antiangiogenic ribozyme (Angiozyme) in the mouse. Antisense Nucleic Add Drug Dev. (1999) 9:271–277.
   PubMedGoogle Scholar
• SANDBERG JA, SPROUL CD, BLANCHARD KS et al.: Acute toxicology and pharmacokinetic assessment of a ribozyme (Angiozyme) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev. (2000)10:153–162.
   PubMedGoogle Scholar
• SAND BERG JA, PARKER VP, BLANCHARD KS et al.: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (Angiozyme) in healthy volunteers. Clin. Pharmacol (2000) 40:1462–1469.
   Google Scholar
• AIGNER A, BUTSCHEID M, KUNKEL P et al: An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int. Cancer (2001) 92:510–517.
   PubMed Web of Science ®Google Scholar
• CZUBAYKO F, LIAUDET- COOPMAN ED, AIGNER A et al: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. (1997) 3:1137–1140.
   PubMed Web of Science ®Google Scholar
• AIGNER A, RENNEBERG H, BOJUNGA J et al.: Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene (2002) 21:5733–5742.
   PubMed Web of Science ®Google Scholar
• THOMPSON ME, JENSEN RA, OBERMILLER PS et al: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. (1995) 9:444–450.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA K, HONDA K, INAMOTO T et al.: Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin. Cancer Res. (1999) 5:1249–1261.
   PubMedGoogle Scholar
• BEGER C, PIERCE LN, KRUGER M et al.: Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Nati Acad. Sci. USA (2001) 98:130–135.
   PubMed Web of Science ®Google Scholar
• PAHL HL: Activators and target genes of Rel/NF-KB transcription factors. Oncogene (1999) 18:6853–6866.
   PubMed Web of Science ®Google Scholar
• WANG CY, CUSACK JC, LIU R et al: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-icB. Nat. Med. (1999) 5:412–417.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M, LIU Y, FONG S et al.: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc. Nati Acad. Sci. USA (2002) 99:3878–3883.
   PubMed Web of Science ®Google Scholar
• IIDA T, KIJIMA H, URATA Yet al.: Hammerhead ribozyme against y-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Thec (2001) 8:803–814.
   Google Scholar
• NAGATA J, KIJIMA H, HATANAKA H et al.: Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochern. Biophys. Res. Commun. (2001) 286:406–413.
   PubMed Web of Science ®Google Scholar
• HATANAKA H, ABE Y, NARUKE M et al: Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. Anti-Cancer Res. (2001) 21:879–885.
   PubMed Web of Science ®Google Scholar
• TEKUR S, HO SM: Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines. MM. Carcinog. (2002) 33:44–55.
   PubMed Web of Science ®Google Scholar
• CAI L, SATOH M, TOHYAMA C et al: Metallothionein in radiation exposure: its induction and protective role. Toxicology (1999) 132:85–98.
   PubMed Web of Science ®Google Scholar
• KONDO Y, WOO ES, MICHALSKA AE et al.: Metallothionein null-cells have increased sensitivity to anticancer drugs. Cancer Res. (1995) 55:2021–2023.
   PubMed Web of Science ®Google Scholar
• SOHN RL, MURRAY MT, SCHWARZ K et al.: In vivo particle mediated delivery of mRNA to mammalian tissues: ballistic and biologic effects. Wound Repair Regen. (2001) 9:287–296.
   PubMed Web of Science ®Google Scholar
• BETTINGERT, CARLISLE RC, READ ML et al.: Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. (2001) 29:3882–3891.
   PubMed Web of Science ®Google Scholar
• TOURRIERE H, CHEBLI K, TAZI J: mRNA degradation machines in eukaryotic cells. Biochimie (2002) 84:821–837.
   PubMed Web of Science ®Google Scholar
• GILBOA E, NAIR SK, LYERLY HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Inman. (1998) 46:82–87.
   PubMed Web of Science ®Google Scholar
• HEISER A, MAURICE MA, YANCEY DR et al.: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. Iinmunol. (2001) 166:2953–2960.
   PubMed Web of Science ®Google Scholar
• HEISER A, COLEMAN D, DANNULL J et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. Clin. Invest. (2002) 109:409–417.
   Google Scholar
• ••This reports demonstrates successful in vivoinduction of PSA-specific immunity using DCs transfected with PSA mRNA in a Phase I trial.
   Google Scholar
• HACKETT NR, KAMINSKY SM, SONDHI D et al: Antivector and antitransgene host responses in gene therapy. Carr: Opin. Mol. Ther: (2000) 2:376–382.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, SUZUKI K, CURIEL DT: Blood clearance rates of adenovirus Type Sin mice. Gen. Virol. (2000) 81:2605–2610.
   PubMed Web of Science ®Google Scholar
• ROTHER RP, FODOR WL, SPRINGHORN JP et al.: A novel mechanism of retrovirus inactivation in human serum mediated by anti-a-galactosyl natural antibody. Exp. Med. (1995) 182:1345–1355.
   PubMed Web of Science ®Google Scholar
• RUSSELL DW, BERGER MS, MILLER AD: The effects of human serum and cerebrospinal-fluid on retroviral vectors and packaging cell-lines. Hum. Gene Ther. (1995) 6:635–641.
   PubMed Web of Science ®Google Scholar
• MARTIGNONE S, MENARD S, BUFALINO R et al.: Prognostic-significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. Natl. Cancer Inst. (1993) 85:398–402.
   Google Scholar
• SANJUAN X, FERNANDEZ PL, MIQUEL R et al: Overexpression of the 67-kD laminin receptor. Correlates with tumour progression in human colorectal carcinoma. Pathol (1996) 179:376–380.
   Google Scholar
• VANDENBRULE FA, CASTRONOVO V, MENARD S et al.: Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur. .1 Cancer (1996) 32A:1598–1602.
   Google Scholar
• TSENG JC, LEVIN B, HIRANO T et al: In vivo antitumor activity of Sindbis viral vectors. Nati Cancer Inst. (2002) 94:1790–1802.
   PubMedGoogle Scholar
• •This reports demonstrates that Sindbis viral vectors efficiently target tumours in vivo resulting in complete tumour regression in 4 out of 5 mice bearing BHK subcutaneous xenografts.
   Google Scholar
• FROLOV I, AGAPOV E, HOFFMAN TA et al.: Selection of RNA replicons capable of persistent non-cytopathic replication in mammalian cells." Virol (1999) 73:3854–3865.
   Google Scholar
• LUNDSTROM K: Alphavirus-based vaccines. Carr: Opin. MM. Ther: (2002) 4:28–34.
   PubMed Web of Science ®Google Scholar
• COLMENERO P, CHEN M, CASTANOS-VELEZ E et al.: Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. Cancer (2002) 98:554–560.
   PubMed Web of Science ®Google Scholar
• YING H, ZAKS TZ, WANG RF et al: Cancer therapy using a self-replicating RNA vaccine. Nat. Med. (1999) 5:823–827.
   PubMed Web of Science ®Google Scholar
• •This report demonstrates prevention of experimental tumour growth in mice by immunisation with naked alphavirus replicon RNA.
   Google Scholar
• CHENG WE HUNG CF, HSU KF et al.: Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. (2002) 13:553–568.
   Google Scholar
• VELDERS MP, MCELHINEY S, CASSETTI MC et al.: Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7. Cancer Res. (2001) 61:7861–7867.
   PubMed Web of Science ®Google Scholar
• DAEMEN T, REGTS J, HOLTROP M et al.: Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther: (2002) 9:85–94.
   PubMed Web of Science ®Google Scholar
• GROMEIER M, LACHMANN S, ROSENFELD MR et al: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Nati Acad. Sci. USA (2000) 97:6803–6808.
   PubMed Web of Science ®Google Scholar
• ANRAKU I, HARVEY TJ, LINEDALE R et al.: Kunjin virus replicon vaccine vectors induce protective CD8+ T cell immunity. Virol (2002) 76:3791–3799.
   Web of Science ®Google Scholar
• CHECK E: Second cancer case halts gene-therapy trials. Nature (2003) 421:305.
   PubMed Web of Science ®Google Scholar
• AGAPOV EV, FROLOV I, LINDENBACH BD et al.: Non-cytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc. Natl. Acad. Sci. USA (1998) 95:12989–12994.
   PubMed Web of Science ®Google Scholar
• KHROMYKH AA, WESTAWAY EG: Subgenomic replicons of the flavivirus Kunjin: construction and applications. Virol (1997) 71:1497–1505.
   Web of Science ®Google Scholar
• •The first published report on construction of the flavivirus replicons and their use for expression of heterologous genes.
   Google Scholar
• PARKS GD, YOUNG VA, KOUMENIS C et al.: Controlled cell killing by a recombinant non-segmented negative-strand RNA virus. Virology (2002) 293:192–203.
   PubMed Web of Science ®Google Scholar
• BERGLUND P, FLEETON MN, SMERDOU C et al: Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine (1999) 17:497–505.
   PubMed Web of Science ®Google Scholar
• FISHER KD, STALLWOOD Y, GREEN NK et al.: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther: (2001) 8:341–348.
   PubMed Web of Science ®Google Scholar
• AIGNER A, FISCHER D, MERDAN T et al.: Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Titer: (2002) 9:1700–1707.
   Google Scholar
• •A novel method is described for exogenous delivery of bioactive ribozymes in vivo without chemical modification.
   Google Scholar
• READ ML, BREMNER KH, OUPICKY D et al.: Vectors based on reducible polycations facilitate intracellular release of nucleic acids. Gene Med. (2003) 5(3):232–245.
   Google Scholar
• SONG E, LEE SK, WANG Jet al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9(3):347–351.
   Google Scholar
• LEWIS DL, HAGSTROM JE, LOOMIS AG et al: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. (2002) 32:107–108.
   PubMed Web of Science ®Google Scholar
• •A method is described for efficient in vivo delivery of siRNAs to organs of postnatal mice and demonstration of effective specific inhibition of transgene expression in a variety of organs.
   Google Scholar
• MARCUCCI G, BYRD JC, DAI G et aL: Phase I and pharmacodynamic studies of G3139, a Bc1-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood (2003) 101(2):425–432.
   PubMed Web of Science ®Google Scholar